Highlights Bristol-Myers Squibb Company Buenos Aires S.E.

Equities

BMY

ARDEUT112877

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
19,082 ^ARS	+3.13%		+8.59%	+15.95%

02:32pm	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
26/06	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	06:02pm	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06	CI
US FDA approves Bristol Myers' colorectal cancer therapy	21/06	RE
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06	MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06	MT
Bristol Myers: Board declares dividend	18/06	CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06	CI
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06	CI
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06	MT
Geron shares surge after U.S. FDA approves blood disorder drug	07/06	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST